Divergent bitter and sweet taste perception intensity in chronic rhinosinusitis patients
© 2020 ARS-AAOA, LLC..
BACKGROUND: Bitter and sweet taste receptors are present in the human upper airway, where they have roles in innate immunity. Previous studies have shown that 1 of the 25 bitter receptors, TAS2R38, responds to specific bacterial signaling molecules and evokes 1 type of a defense response in the upper airway, whereas ligands of sweet receptors suppress other types of defense responses.
METHODS: We examined whether other bitter taste receptors might also be involved in innate immunity by using sensory responses to bitter compounds that are not ligands of TAS2R38 (quinine and denatonium benzoate) to assess the sensitivity of other bitter receptors in chronic rhinosinusitis (CRS) patients. CRS patients with (n = 426) and without (n = 226) nasal polyps and controls (n = 356) rated the intensity of quinine, denatonium benzoate, phenylthiocarbamide (PTC; a ligand for TAS2R38), sucrose, and salt.
RESULTS: CRS patients rated the bitter compounds denatonium benzoate and quinine as less intense and sucrose as more intense than did controls (false discovery rate [FDR] <0.05) and CRS patients and controls did not differ in their ratings of salt (FDR >0.05). PTC bitter taste intensity differed between patient and control groups but were less marked than those previously reported. Though differences were statistically significant, overall effect sizes were small.
CONCLUSION: CRS patients report bitter stimuli as less intense but sweet stimuli as more intense than do control subjects. We speculate that taste responses may reflect the competence of sinonasal innate immunity mediated by taste receptor function, and thus a taste test may have potential for clinical utility in CRS patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
International forum of allergy & rhinology - 11(2021), 5 vom: 27. Mai, Seite 857-865 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lin, Cailu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.09.2021 Date Revised 03.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/alr.22686 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314193618 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314193618 | ||
| 003 | DE-627 | ||
| 005 | 20231225152216.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/alr.22686 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314193618 | ||
| 035 | |a (NLM)32846055 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lin, Cailu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Divergent bitter and sweet taste perception intensity in chronic rhinosinusitis patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2021 | ||
| 500 | |a Date Revised 03.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 ARS-AAOA, LLC. | ||
| 520 | |a BACKGROUND: Bitter and sweet taste receptors are present in the human upper airway, where they have roles in innate immunity. Previous studies have shown that 1 of the 25 bitter receptors, TAS2R38, responds to specific bacterial signaling molecules and evokes 1 type of a defense response in the upper airway, whereas ligands of sweet receptors suppress other types of defense responses | ||
| 520 | |a METHODS: We examined whether other bitter taste receptors might also be involved in innate immunity by using sensory responses to bitter compounds that are not ligands of TAS2R38 (quinine and denatonium benzoate) to assess the sensitivity of other bitter receptors in chronic rhinosinusitis (CRS) patients. CRS patients with (n = 426) and without (n = 226) nasal polyps and controls (n = 356) rated the intensity of quinine, denatonium benzoate, phenylthiocarbamide (PTC; a ligand for TAS2R38), sucrose, and salt | ||
| 520 | |a RESULTS: CRS patients rated the bitter compounds denatonium benzoate and quinine as less intense and sucrose as more intense than did controls (false discovery rate [FDR] <0.05) and CRS patients and controls did not differ in their ratings of salt (FDR >0.05). PTC bitter taste intensity differed between patient and control groups but were less marked than those previously reported. Though differences were statistically significant, overall effect sizes were small | ||
| 520 | |a CONCLUSION: CRS patients report bitter stimuli as less intense but sweet stimuli as more intense than do control subjects. We speculate that taste responses may reflect the competence of sinonasal innate immunity mediated by taste receptor function, and thus a taste test may have potential for clinical utility in CRS patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a bitter taste receptors | |
| 650 | 4 | |a bitterness | |
| 650 | 4 | |a chronic rhinosinusitis | |
| 650 | 4 | |a sensory perception | |
| 650 | 4 | |a sweet taste receptors | |
| 650 | 7 | |a Receptors, G-Protein-Coupled |2 NLM | |
| 700 | 1 | |a Civantos, Alyssa M |e verfasserin |4 aut | |
| 700 | 1 | |a Arnold, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Stevens, Elizabeth M |e verfasserin |4 aut | |
| 700 | 1 | |a Cowart, Beverly J |e verfasserin |4 aut | |
| 700 | 1 | |a Colquitt, Lauren R |e verfasserin |4 aut | |
| 700 | 1 | |a Mansfield, Corrine |e verfasserin |4 aut | |
| 700 | 1 | |a Kennedy, David W |e verfasserin |4 aut | |
| 700 | 1 | |a Brooks, Steven G |e verfasserin |4 aut | |
| 700 | 1 | |a Workman, Alan D |e verfasserin |4 aut | |
| 700 | 1 | |a Blasetti, Mariel T |e verfasserin |4 aut | |
| 700 | 1 | |a Kohanski, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Doghramji, Laurel |e verfasserin |4 aut | |
| 700 | 1 | |a Douglas, Jennifer E |e verfasserin |4 aut | |
| 700 | 1 | |a Maina, Ivy W |e verfasserin |4 aut | |
| 700 | 1 | |a Palmer, James N |e verfasserin |4 aut | |
| 700 | 1 | |a Adappa, Nithin D |e verfasserin |4 aut | |
| 700 | 1 | |a Reed, Danielle R |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Noam A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International forum of allergy & rhinology |d 2011 |g 11(2021), 5 vom: 27. Mai, Seite 857-865 |w (DE-627)NLM209105178 |x 2042-6984 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:5 |g day:27 |g month:05 |g pages:857-865 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/alr.22686 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 5 |b 27 |c 05 |h 857-865 | ||